Ginkgo Bioworks
DNA
$0.24 (-2.97%)
1D
1W
3M
1Y
5Y
ALL
Ginkgo Bioworks Holdings, Inc., formerly Spinning Eagle Acquisition Corp, is engaged in building a platform to program cells. The Company's platform is used to program cells on behalf of its customers. Its cell programs are designed to enable biological production of products such as therapeutics, key food ingredients, and chemicals derived from petroleum. The Company's platform is used to design, write, and debug deoxyribonucleic acid (DNA) code in engineered organisms to execute programs for its customers. The Company’s platform comprises of equipment, robotic automation, software, data pipelines and tools, and standard operating procedures for genetic engineering, fermentation, and analytics, a library of proprietary genetic assets and associated performance data; and developers and operators of the foundry and codebase. It serves industries, including chemicals, agriculture, food, consumer products, and pharmaceuticals.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
PRNewsWire • 7 days ago • DNA
Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of GrainBusiness Wire • 14 days ago • DNA
Plex Research Partners With Ginkgo Bioworks on Artificial Intelligence (AI)-Powered Drug Discovery to Identify Novel Disease Mechanisms and PathwaysZacks Investment Research • 16 days ago • DNA
Here's Why Ginkgo Bioworks (DNA) is Poised for a Turnaround After Losing -28.84% in 4 WeeksZacks Investment Research • 21 days ago • DNA
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research • 27 days ago • DNA
Ginkgo Bioworks Holdings, Inc. (DNA) Surpasses Market Returns: Some Facts Worth KnowingCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.